Stock MRK MERCK & CO., INC.
Add to a list

Merck & Co., Inc. Stock

Stocks

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX
Other stock markets
 10:19:38 2026-07-17 EDT 		5-day change 1st Jan Change
130.44 USD +2.20% Intraday chart for Merck & Co., Inc. +6.04% +24.45%
04:42am GSK stops development of chronic cough drug after late-stage trial miss RE
07-16 Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers CI

Valuation: Merck & Co., Inc.

Market Cap 315B 276B 255B 234B 443B 30,375B 450B 3,039B 1,194B 14,833B 1,184B 1,158B 51,210B P/E 2026 *
65x
P/E 2027 * 15.5x
Enterprise Value 351B 307B 284B 260B 493B 33,833B 502B 3,385B 1,330B 16,522B 1,319B 1,290B 57,041B EV / Sales 2026 *
5.25x
EV / Sales 2027 * 4.83x
Free-Float
69%
Yield 2026 *
2.66%
Yield 2027 * 2.73%
* Estimated data More valuation ratios

Chart: Merck & Co., Inc.

Dynamic Chart

Latest news : Merck & Co., Inc.

04:42am GSK stops development of chronic cough drug after late-stage trial miss RE
07-16 Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers CI
07-16 Merck's HIV Pipeline Nears Key Inflection Point Ahead of ISLEND Data, RBC Says MT
07-16 US green light for a new Merck cholesterol drug Zonebourse
07-16 US green light for a new Merck cholesterol drug Zonebourse
07-16 Merck & Co., Inc. Receives U.S. FDA Approval For LIPFENDRA As The First Once-Daily Oral PCSK9 Inhibitor To Reduce LDL-C In Adults With Hypercholesterolemia CI
07-16 Merck Receives FDA Approval for Cholesterol Pill Lipfendra MT
07-16 Merck gets US FDA nod for first-in-its-class oral cholesterol drug RE
07-15 US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions MT
07-15 Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Economic Reports MT
07-15 Merck's Keytruda Meets Main Goal in Phase 3 Endometrial Cancer Trial MT
07-15 Merck Announces KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient Tumors Compared to Chemotherapy CI
07-13 Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug MT
More news

Last Transcript: Merck & Co., Inc.

Logo Merck & Co., Inc.
Merck & Co., Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM
06-09
More transcripts

Analysts' recommendations: Merck & Co., Inc.

07-13 BMO Capital Adjusts Price Target on Merck & Co to $142 From $135, Maintains Outperform Rating MT
07-13 JPMorgan Adjusts Price Target on Merck to $140 From $135, Maintains Overweight Rating MT
07-10 Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says MT
07-10 Berenberg Adjusts Price Target on Merck to $127 From $125, Keeps Hold Rating MT
07-08 Merck Likely to Post Inline Q2 Revenue, RBC Says MT
More recommendations

Press Releases: Merck & Co., Inc.

07-16 Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia BU
07-15 Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026 BU
07-15 KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BU
07-10 FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC) BU
07-01 Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 BU
More press releases

News in other languages: Merck & Co., Inc.

03:22am Gestern an der Wall Street: Halbleitersektor belastet die Börsen
07-16 Feu vert US à un nouvel anticholestérol de Merck
07-16 Merck & Co erhält US-Zulassung für neuartige Cholesterin-Pille
07-01 Afternoon Meeting: Julio arranca bajo la sombra de la Reserva Federal
07-01 Juli-Auftakt unter einer Fed-förmigen Wolke
More news

Quotes and Performance

1 day+2.38%
1 week+6.04%
Current month+1.95%
1 month+13.48%
3 months+10.02%
6 months+19.69%
Current year+24.45%
More quotes

Course Extremes

1 week 120.16
Extreme 120.16
 131.6
1 month 111.57
Extreme 111.57
 131.6
Current year 104.43
Extreme 104.43
 131.6
1 year 76.66
Extreme 76.66
 131.6
3 years 73.31
Extreme 73.31
 134.63
5 years 70.89
Extreme 70.89
 134.63
10 years 52.83
Extreme 52.83
 134.63
More quotes

Managers and Directors: Merck & Co., Inc.

Manager TitleAgeSince
Robert Davis CEO
 Chief Executive Officer 59 2021-06-30
Caroline Litchfield DFI
 Director of Finance/CFO 57 2021-03-31
Marjorie Green CTO
 Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Tom Glocer BRD
 Director/Board Member 65 2007-11-26
Patricia Russo BRD
 Director/Board Member 73 1995-08-31
Robert Davis CHM
 Chairman 59 2022-11-30
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap.
6/30/26
Surendralal Karsanbhai
Other

Director

126 0.0000%
6/30/26
Christine Seidman
Other

Director

63 0.0000%
6/30/26
Mary Coe
Other

Director

233 0.0000%
Transaction History

Specialty & Advanced Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
MERCK & CO., INC. Stock Merck & Co., Inc.
+2.18%+6.04%+60.70%+24.09% 315B
MERCK KGAA Stock Merck KGaA
-2.10%-2.79%+21.74%-8.74% 68.62B
HALOZYME THERAPEUTICS, INC. Stock Halozyme Therapeutics, Inc.
+0.91%+3.33%+36.21%+95.52% 9.2B
KYOWA KIRIN CO., LTD. Stock Kyowa Kirin Co., Ltd.
+0.34%+0.51%+4.67%-0.69% 8.52B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-3.05%+0.42%+6.92%+28.13% 4.04B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
+1.53%-1.00%-18.56%+3.79% 4.2B
YUHAN CORPORATION Stock Yuhan Corporation
+1.87%+5.04%-37.18%+24.94% 3.56B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+1.40%+0.76%+45.37%+65.92% 2.8B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
-0.81%+7.81%+12.16%-16.29% 2.26B
SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. Stock Shenzhen Chipscreen Biosciences Co., Ltd.
-3.46%+13.29%-11.84%+40.22% 2.01B
Average -0.10%+0.37%+12.02%+25.69% 42.04B
Weighted average by Cap. +1.46%-1.70%+49.82%+19.77%
See all sector performances

Financials

2026 *2027 *
Net sales 66.91B 58.49B 54.09B 49.63B 93.94B 6,448B 95.57B 645B 253B 3,149B 251B 246B 10,870B 70.11B 61.28B 56.67B 52.01B 98.43B 6,756B 100B 676B 266B 3,299B 263B 258B 11,390B
Net income 5.26B 4.6B 4.25B 3.9B 7.38B 507B 7.51B 50.7B 19.92B 247B 19.75B 19.32B 854B 20.1B 17.57B 16.25B 14.91B 28.22B 1,937B 28.71B 194B 76.13B 946B 75.5B 73.84B 3,266B
Net Debt 35.89B 31.38B 29.02B 26.63B 50.39B 3,459B 51.27B 346B 136B 1,689B 135B 132B 5,831B 23.2B 20.28B 18.75B 17.21B 32.57B 2,236B 33.14B 224B 87.86B 1,092B 87.13B 85.21B 3,769B
* Estimated data More financial data

Company Profile

Logo Merck & Co., Inc.
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.9%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (15.5%); - sale of animal health products (9.8%); - other (0.8%). Net sales are distributed geographically as follows: the United States (56.2%), Europe/Middle East/Africa (22.4%), Latin America (5.2%), Asia/Pacific (4.6%), Japan (4.2%), China (3%) and other (4.4%).
Employees
74,000
Sector
Pharmaceuticals
Calendar
Earnings release - Q2 2026
More about the company

Quotes

Date Price Change Volume
26-07-17 US$131.13 +2.74% 2,762,830
26-07-16 US$127.63 +3.25% 13,038,762
26-07-15 US$123.61 +2.34% 9,053,781
26-07-14 US$120.78 -2.62% 9,932,947
26-07-13 US$124.03 +0.40% 5,225,798

Delayed Quote NYSE

More quotes

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
127.63USD
Average target price
134.04USD
Spread / Average Target
+5.02%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Stocks
  3. MRK Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition